Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy. (November 2022)

• Record Type: Journal Article
• Authors: Im, Eunji; Sim, Deok Yong; Lee, Hyo-Jung; Park, Ji Eon; Park, Woon Yi; Ko, SeongGyu; Kim, Bonglee; Shim, Bum Sang; Kim, Sung-Hoon
• Is Part Of: Seminars in cancer biology. Volume 86(2023)Part 2
• Page Start: 1066
• Page End: 1075
• Publication Date: 2022-11
• Subjects: APCs antigen presenting cells -- CAFs cancer‐associated fibroblasts -- CAR chimeric antigen receptors -- CTLA‐4 cytotoxic T lymphocyte-associated antigen-4 -- DCs Dendritic cells -- EGFR Epidermal growth factor receptor -- EMT Epithelial mesenchymal transition -- ICB immune checkpoint blockade -- JAK Janus kinases -- LAG-3 lymphocyte activation gene-3 -- MDSCs myeloid-derived suppressor cells -- MMPs matrix metalloproteinases -- mTOR mammalian target of rapamycin -- NSCLCs non-small cell lung cancers -- PD-1 programmed cell death protein-1 -- PD-L1 programmed cell death-ligand 1 -- PI3K phosphoinositide 3-kinase -- PFS progression-free survival -- PSGL-1 P-selectin glycoprotein ligand-1 -- PTEN phosphatase and tensin homolog -- STAT3 signal transducer and activator of transcription 3 -- TAMs tumor-associated macrophages -- TCR T cell receptor -- TIGIT T cell immunoreceptor with Ig and ITIM domains -- TILs tumor infiltrating leukocytes -- TIM-3 T cell immunoglobulin and mucin domain 3 -- TME tumor microenvironment -- VEGFR vascular endothelial growth factor receptor -- VISTA V-domain Ig-containing suppressor of T cell activation; VISTA -- Cancer prognosis biomarker -- Immune function -- Clinical implications -- VISTA antagonists; Cancer -- Periodicals; Neoplasms -- Periodicals; Review Literature; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.semcancer.2021.08.008
• Languages: English
• ISSNs: 1044-579X

Abstract

Abstract: Since cancer immunotherapy with immune checkpoint inhibitors of PD/PDL-1 and CTLA-4 limited efficacy to the patients due to resistance during the current decade, novel target is required for customized treatment due to tumor heterogeneity. V-domain Ig-containing suppressor of T cell activation (VISTA), a programmed death protein-1(PD-1) homolog expressed on T cells and on antigen presenting cells(APC), has emerged as a new target in several cancers. Though VISTA inhibitors including CA-170 are considered attractive in cancer immunotherapy to date, the information on VISTA as a potent biomarker of cancer prognosis and its combination therapy is still lacking to date. Thus, in this review, we discussed extracellular domain, ligands, expression, immune functions and clinical implications of VISTA and finally suggested conclusion and perspectives.